Cargando…

DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma

Rationale: Although sunitinib has been shown to improve the survival rate of advanced renal cell carcinoma (RCC) patients, poor drug response is a major challenge that reduces patient benefit. It is important to elucidate the underlying mechanism so that the therapeutic response to sunitinib can be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Tangliang, Bao, Yi, Gan, Xinxin, Wang, Jie, Chen, Qiong, Dai, Zhihui, Liu, Bing, Wang, Anbang, Sun, Shuhan, Yang, Fu, Wang, Linhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735520/ https://www.ncbi.nlm.nih.gov/pubmed/31534544 http://dx.doi.org/10.7150/thno.35572

Ejemplares similares

QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis
por: Zhao, Tangliang, et al.
Publicado: (2021)

Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer
por: Wang, Anbang, et al.
Publicado: (2019)

Pyk2 promotes tumor progression in renal cell carcinoma
por: Zhao, Tangliang, et al.
Publicado: (2018)

Identification and Epigenetic Analysis of a Maternally Imprinted Gene Qpct
por: Guo, Jing, et al.
Publicado: (2015)

Cell Adhesion-Related Molecules Play a Key Role in Renal Cancer Progression by Multinetwork Analysis
por: Wang, Anbang, et al.
Publicado: (2019)

Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response
por: Bao, Yi, et al.
Publicado: (2018)

siRNA screen identifies QPCT as a druggable target for Huntington’s disease
por: Jimenez-Sanchez, Maria, et al.
Publicado: (2015)

Methyltransferase‐like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1
por: Liu, Tao, et al.
Publicado: (2021)

Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis
por: Jiang, Aimin, et al.
Publicado: (2022)

Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma
por: Jiang, Aimin, et al.
Publicado: (2021)

Apicidin confers promising therapeutic effect on acute myeloid leukemia cells via increasing QPCT expression
por: Liu, Lulu, et al.
Publicado: (2023)

Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis
por: Schloesser, Daniela, et al.
Publicado: (2022)

Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity
por: Jiang, Aimin, et al.
Publicado: (2022)

Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice
por: Fan, Tingting, et al.
Publicado: (2017)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma
por: Bao, Yewei, et al.
Publicado: (2021)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

FTO promotes liver inflammation by suppressing m6A mRNA methylation of IL-17RA
por: Gan, Xiaojie, et al.
Publicado: (2022)

Mechanism of the Exchange Reaction in HRAS from Multiscale Modeling
por: Kapoor, Abhijeet, et al.
Publicado: (2014)

HRAS mutation prevalence and associated expression patterns in pheochromocytoma
por: Stenman, Adam, et al.
Publicado: (2016)

Phacomatosis pigmentokeratotica and precocious puberty associated with HRAS mutation
por: Martin, R.J., et al.
Publicado: (2017)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
por: Chen, Ying-Shou, et al.
Publicado: (2009)

A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma
por: Jiang, Aimin, et al.
Publicado: (2022)

WDR76 regulates 5-fluorouracil sensitivity in colon cancer via HRAS
por: Hu, Yunlong, et al.
Publicado: (2023)

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma
por: Jiang, Aimin, et al.
Publicado: (2022)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

MTH1 expression is required for effective transformation by oncogenic HRAS
por: Giribaldi, Maria G., et al.
Publicado: (2015)

The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma
por: Wan, Xiaohua, et al.
Publicado: (2017)

Analysis of FGFR3 and HRAS genes in patients with bladder cancer
por: Homami, Ameneh, et al.
Publicado: (2020)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
por: Wu, Zeshen, et al.
Publicado: (2022)

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma
por: Jiang, Aimin, et al.
Publicado: (2023)

A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells
por: Qu, Le, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_havnm0s1h8fqekbgf3iu092pe0